BISOLVON LINCTUS DA

Indications

• Chronic obstructive pulmonary disease (COPD)
• Bronchitis
• Asthma
• Respiratory infections with mucus hypersecretion

Dosage

Children: Refer to specific dosing guidelines for children in the BNF for Children or other trusted medical sources.

Adults: Refer to specific dosing guidelines in the BNF or other trusted medical sources.

Mechanism of action

Brohexine acts by enhancing the production and secretion of serous mucus from the respiratory tract, which helps to liquefy and clear mucus. It also stimulates the activity of cilia in the respiratory epithelium, promoting mucociliary clearance. The drug has been shown to alter the rheological properties of mucus, reducing its viscosity and elasticity.

Pharmacodynamics

The pharmacodynamic profile of brohexine includes its ability to improve respiratory function by enhancing mucus clearance. This is particularly beneficial in patients with respiratory diseases where mucus accumulation can lead to obstruction and infection. Brohexine has anti-inflammatory properties, which may also contribute to its therapeutic effects in respiratory conditions.

Pharmacokinetics

Brohexine is well absorbed after oral administration, and it undergoes extensive first-pass metabolism. The onset of action typically occurs within a few hours, with peak plasma concentrations reached within 1 to 2 hours. The drug is primarily metabolized in the liver, and its metabolites are excreted in the urine. The elimination half-life of brohexine is approximately 8 to 12 hours.

Adverse effects

• Gastrointestinal disturbances
• Nausea
• Vomiting
• Diarrhea
• Allergic reactions such as rash or pruritus

Precautions

• Caution in patients with peptic ulcer disease
• Use with care in patients with severe liver or kidney impairment

Pregnancy

Brohexine should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus, as there is limited data on its safety.

Breast-feeding

Brohexine is excreted in breast milk; caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat.

Formulations

• Oral solution
• Tablets

Indications

• Bronchospasm
• Asthma
• Chronic obstructive pulmonary disease (COPD)

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Orciprenaline stimulates the β2-adrenergic receptors in the lungs, uterus, and vasculature supplying skeletal muscles, acting as a moderately selective agonist. Its actions are mediated through the intracellular signaling pathway involving cyclic adenosine monophosphate (cAMP), which is increased by the activation of adenylate cyclase, leading to relaxation of bronchial smooth muscles and inhibition of inflammatory mediator release from mast cells.

Pharmacodynamics

As a synthetic amine similar to isoproterenol, orciprenaline's pharmacological effects are primarily due to its action on beta-adrenergic receptors. The stimulation of these receptors results in the activation of adenylate cyclase, promoting the conversion of ATP to cAMP. Elevated cAMP levels induce relaxation of bronchial smooth muscles and suppress the release of inflammatory mediators, contributing to its efficacy as a bronchodilator.

Pharmacokinetics

Orciprenaline is administered via inhalation or orally. Its onset of action typically occurs within minutes when inhaled, and its effects can last for several hours. The drug is metabolized in the liver and excreted primarily through the urine. The half-life and specific metabolic pathways have not been detailed in the available data.

Adverse effects

• Tachycardia
• Palpitations
• Tremors
• Headache
• Nausea
• Dizziness
• Hypokalemia

Interactions

• Other sympathomimetics may potentiate the effect of orciprenaline
• Beta-blockers may reduce the effectiveness of orciprenaline
• Corticosteroids may enhance the effect of orciprenaline

Precautions

• Use with caution in patients with cardiovascular disorders
• Monitor potassium levels in patients at risk of hypokalemia
• Caution in patients with hyperthyroidism, diabetes mellitus, or seizure disorders

Pregnancy

Orciprenaline should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is unknown whether orciprenaline is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place away from light. Do not freeze.

Formulations

• Inhalation solution
• Metered dose inhaler

Mechanism of action

Orciprenaline stimulates the β2-adrenergic receptor expressed in the lungs, uterus, and vasculature supplying skeletal muscles by acting as a moderately selective agonist. It exerts minimal or no effect on alpha-adrenergic receptors. Intracellularly, the actions of orciprenaline are mediated by cAMP, the production of which is augmented by beta stimulation. The drug is believed to work by activating adenylate cyclase, the enzyme responsible for producing the cellular mediator cAMP.

Pharmacodynamics

Orciprenaline (also known as metaproterenol), a synthetic amine, is structurally and pharmacologically similar to isoproterenol. Orciprenaline is used exclusively as a bronchodilator. The pharmacological effects of beta adrenergic agonist drugs, such as orciprenaline, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased cAMP levels lead to relaxation of bronchial smooth muscles and inhibition of the release of inalammatory mediators from mast cells that are involved in promoting immediate hypersensitivity .